Moritz Binder, MD, MPH, Mayo Clinic, Rochester, MN, discusses the role of bone marrow stromal cells in high-risk multiple myeloma. Dr Binder explains that a recent study has shown that stromal cells remodel the epigenome upon interaction with multiple myeloma cells and induce dynamic gene expression changes related to high-risk features. Targeting these genes might constitute a promising therapeutic strategy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
